Vaxcyte, Inc. Common Stock PCVX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:26:30.027Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:25:35.90079734Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:26:29.684444+00:00
Vaxcyte, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 74.67 | 71.4% | 12.0% | 61.38 | 73.6% | 10.4% |
| 25Δ | 73.53 | 72.9% | 10.8% | 62.58 | 73.4% | 9.1% |
| 30Δ | 72.39 | 74.4% | 9.6% | 63.78 | 73.2% | 7.8% |
| 35Δ | 71.25 | 76.0% | 8.4% | 64.98 | 73.0% | 6.5% |
| 40Δ | 70.11 | 77.5% | 7.3% | 65.61 | 68.2% | 5.8% |
| 45Δ | 69.00 | 80.4% | 6.5% | 66.23 | 63.2% | 5.0% |
| 50Δ | 67.89 | 83.5% | 5.8% | 66.85 | 58.2% | 4.3% |
| 55Δ | 66.77 | 86.6% | 5.2% | 67.47 | 53.2% | 3.6% |
| 60Δ | 65.66 | 89.6% | 4.5% | 68.10 | 48.2% | 2.9% |
| 65Δ | 64.48 | 91.0% | 3.8% | 68.72 | 43.3% | 2.1% |
| 70Δ | 63.19 | 89.8% | 3.1% | 69.34 | 38.3% | 1.4% |
| 75Δ | 61.90 | 88.6% | 2.5% | 69.96 | 33.3% | 0.7% |
| 80Δ | 60.60 | 87.5% | 1.8% | |||
20Δ
- Pseudo strike
- 74.67
- IV
- 71.4%
- B/E move
- 12.0%
- Pseudo strike
- 61.38
- IV
- 73.6%
- B/E move
- 10.4%
25Δ
- Pseudo strike
- 73.53
- IV
- 72.9%
- B/E move
- 10.8%
- Pseudo strike
- 62.58
- IV
- 73.4%
- B/E move
- 9.1%
30Δ
- Pseudo strike
- 72.39
- IV
- 74.4%
- B/E move
- 9.6%
- Pseudo strike
- 63.78
- IV
- 73.2%
- B/E move
- 7.8%
35Δ
- Pseudo strike
- 71.25
- IV
- 76.0%
- B/E move
- 8.4%
- Pseudo strike
- 64.98
- IV
- 73.0%
- B/E move
- 6.5%
40Δ
- Pseudo strike
- 70.11
- IV
- 77.5%
- B/E move
- 7.3%
- Pseudo strike
- 65.61
- IV
- 68.2%
- B/E move
- 5.8%
45Δ
- Pseudo strike
- 69.00
- IV
- 80.4%
- B/E move
- 6.5%
- Pseudo strike
- 66.23
- IV
- 63.2%
- B/E move
- 5.0%
50Δ
- Pseudo strike
- 67.89
- IV
- 83.5%
- B/E move
- 5.8%
- Pseudo strike
- 66.85
- IV
- 58.2%
- B/E move
- 4.3%
55Δ
- Pseudo strike
- 66.77
- IV
- 86.6%
- B/E move
- 5.2%
- Pseudo strike
- 67.47
- IV
- 53.2%
- B/E move
- 3.6%
60Δ
- Pseudo strike
- 65.66
- IV
- 89.6%
- B/E move
- 4.5%
- Pseudo strike
- 68.10
- IV
- 48.2%
- B/E move
- 2.9%
65Δ
- Pseudo strike
- 64.48
- IV
- 91.0%
- B/E move
- 3.8%
- Pseudo strike
- 68.72
- IV
- 43.3%
- B/E move
- 2.1%
70Δ
- Pseudo strike
- 63.19
- IV
- 89.8%
- B/E move
- 3.1%
- Pseudo strike
- 69.34
- IV
- 38.3%
- B/E move
- 1.4%
75Δ
- Pseudo strike
- 61.90
- IV
- 88.6%
- B/E move
- 2.5%
- Pseudo strike
- 69.96
- IV
- 33.3%
- B/E move
- 0.7%
80Δ
- Pseudo strike
- 60.60
- IV
- 87.5%
- B/E move
- 1.8%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 62.76% | |
| 63.15% | |
| 64.05% | |
| 65.63% | |
| 65.50% | |
| 65.68% | |
| 66.17% | |
| 65.61% | |
| 65.23% | |
| 65.77% | |
| 65.91% | |
| 65.68% | |
| 63.60% | |
| 66.06% | |
| 84.00% | |
| 80.87% | |
| 86.45% | |
| 82.92% | |
| 89.79% | |
| 96.09% | |
| 97.04% | |
| 90.70% | |
| 92.60% | |
| 91.72% | |
| 91.24% | |
| 89.62% | |
| 98.06% | |
| 98.49% | |
| 100.04% | |
| 102.01% | |
| 101.26% | |
| 64.03% | |
| 52.40% | |
| 50.47% | |
| 50.29% | |
| 50.25% | |
| 52.87% | |
| 49.97% | |
| 50.82% | |
| 51.14% | |
| 53.71% | |
| 53.23% | |
| 53.57% | |
| 53.70% | |
| 55.95% | |
| 55.78% | |
| 56.74% | |
| 55.38% |
Biotechnology
PDSB
PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies. The company is headquartered in Florham…
More →PEPG
PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious neurological and…
More →PGEN
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
More →PHAT
Description unavailable
More →PHVS
Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Leiden, the…
More →PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary…
More →